Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer by McClurg, Urszula L et al.
Oncotarget37724www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 35
Ubiquitin-specific protease 12 interacting partners Uaf-1 and 
WDR20 are potential therapeutic targets in prostate cancer
Urszula L. McClurg1, Victoria J. Harle1, Arash Nabbi2, Amanda Batalha-Pereira1, 
Scott Walker1, Kelly Coffey1, Luke Gaughan1, Stuart RC McCracken1 and Craig N. 
Robson1
1 Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical 
School, Newcastle University, Newcastle upon Tyne, United Kingdom
2 Department of Biochemistry and Molecular Biology, Southern Alberta Cancer Research Institute, Cumming School of 
Medicine, University of Calgary, Calgary, AB, Canada
Correspondence to: Craig N. Robson, email: craig.robson@ncl.ac.uk
Keywords: androgen receptor, deubiquitination, prostate cancer, Usp12, UAF1
Received: September 25, 2015 Accepted: September 28, 2015 Published: October 10, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
The androgen receptor (AR) is a key transcription factor in the initiation 
and progression of prostate cancer (PC) and is a major therapeutic target for the 
treatment of advanced disease. Unfortunately, current therapies are not curative for 
castration resistant PC and a better understanding of AR regulation could identify 
novel therapeutic targets and biomarkers to aid treatment of this disease. The AR is 
known to be regulated by a number of post-translational modifications and we have 
recently identified the deubiquitinating enzyme Usp12 as a positive regulator of AR. 
We determined that Usp12 deubiquitinates the AR resulting in elevated receptor 
stability and activity. Furthermore, Usp12 silencing was shown to reduce proliferation 
of PC cells.
Usp12 is known to require the co-factors Uaf-1 and WDR20 for catalytic activity. 
In this report we focus further on the role of Uaf-1 and WDR20 in Usp12 regulation and 
investigate if these co-factors are also required for controlling AR activity. Firstly, we 
confirm the presence of the Usp12/Uaf-1/WDR20 complex in PC cells and demonstrate 
the importance of Uaf-1 and WDR20 for Usp12 stabilisation. Consequently, we show 
that individual silencing of either Uaf-1 or WDR20 is sufficient to abrogate the activity 
of the Usp12 complex and down-regulate AR-mediated transcription via receptor 
destabilisation resulting in increased apoptosis and decreased colony forming ability 
of PC cells. Moreover, expression of both Uaf-1 and WDR20 is higher in PC tissue 
compared to benign controls. Overall these results highlight the potential importance 
of the Usp12/Uaf-1/WDR20 complex in AR regulation and PC progression.
Highlights:
• Androgen receptor is a key transcriptional regulator in prostate cancer
• Usp12/Uaf-1/WDR20 complex plays a crucial role in androgen receptor 
stability and activity
• Destabilising an individual Usp12/Uaf-1/WDR20 complex member reduces 
the protein levels of the whole complex and diminishes androgen receptor activity
• Protein levels of all members of the Usp12/Uaf-1/WDR20 complex are 
significantly increased in PC
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INTRODUCTION
Prostate cancer (PC) is the most commonly 
diagnosed male malignancy in the United States [1]. The 
androgen receptor (AR) is a nuclear hormone receptor 
with a key role in regulating the transcription of genes 
required for PC growth and progression, therefore the AR 
axis is a major focus of current therapies for advanced 
PC [2]. Unfortunately, despite an initial response these 
approaches invariably fail due to aberrant AR signalling 
mediated by receptor mutations and splice variants, AR 
amplification and ligand-independent AR activation [3] 
resulting in the development of castrate-resistant prostate 
cancer (CRPC). The current lack of curative therapy for 
late stage PC highlights the need for both new therapeutic 
targets to overcome resistance as well as novel biomarkers 
to aid early identification of PC and allow better patient 
stratification.
The AR itself is subject to tight regulation by a 
series of post-translational modifications, including 
acetylation, methylation, phosphorylation, sumoylation 
and ubiquitination [4]; [5]; [6]; [7]; [8]; [9]; [10]. Proteins 
involved in the upstream regulation of the AR are 
therefore interesting therapeutic targets as targeting them 
could provide an additional therapeutic opportunity for 
CRPC [11]. We have recently identified the deubiquitinase 
(DUB), ubiquitin specific protease 12 (Usp12) as a positive 
regulator of the AR responsible for deubiquitinating and 
subsequently stabilising the receptor. Usp12 acts as an AR 
co-activator both directly by deubiquitinating the AR [12] 
and indirectly by regulating AR-AKT cross-talk [13]. We 
further established that Usp12 depletion reduced PC cell 
proliferation and induced apoptosis, furthermore Usp12 
levels are increased in PC tissue [12]. 
Usp12 is a highly conserved protein with a high 
degree of homology to Usp46 and to a lesser extent 
Usp1. To date the only other reported targets of Usp12 
are histones H2A and H2B [14], non-activated Notch [15] 
and the phosphatases PHLPP and PHLPPL [13]. Usp1-
associated factor 1 (Uaf-1) is a WD40 repeat (WDR) 
containing protein essential for Usp12 activity, this 
complex is additionally further stabilised by WDR20 [16-
18]. 
In this paper we have further interrogated how the 
Usp12 complex functions and investigated the effects 
of depleting Uaf-1 or WDR20 on Usp12 activity and 
subsequent destabilisation of the AR. The rationale 
behind this is that due to high homology within the 
catalytic domains of DUBs it is predicted that developing 
selective drugs is likely to be problematic [19]. Therefore, 
targeting DUB cofactors such as Uaf-1 and WDR20 
directly or targeting DUB-cofactor interactions may 
allow the development of more targeted therapeutics [11]. 
This has already been evidenced by the development of 
therapeutics aimed at the Usp1-Uaf-1 complex, which 
have been shown to reverse cisplatin-resistance in non-
small lung cancer cells [20, 21]. 
We have further investigated the regulation of Usp12 
by Uaf-1 and WDR20 and shown that these two co-factors 
stabilise Usp12 at the protein level. Depletion of any of 
the complex members affects the transcript levels of the 
Usp12 binding partners. We have established an essential 
role for the Uaf-1 and WDR20 proteins in AR regulation 
and demonstrated that a reduction in either one of these 
proteins reduces AR stability, transcriptional activity and 
importantly PC cell survival. We have also determined that 
Uaf-1 and WDR20 are both overexpressed in PC tissue 
indicating that they could be promising PC biomarkers. 
Overall, this work further highlights the potential of the 
Usp12 complex as a potential therapeutic drug target in 
PC. 
RESULTS
Usp12, Uaf-1 and WDR20 form a complex acting 
within a positive feedback loop in PC cells
Usp12 is known to form a complex with Uaf-1 and 
WDR20 [16, 17]. To confirm the formation of this complex 
WDR20, Uaf-1 and Usp12 were overexpressed followed 
by exogenous WDR20 immunoprecipitation. Subsequent 
immunoblotting confirmed the interaction between these 
three proteins and interestingly revealed that Uaf-1 does 
not directly interact with WDR20 in the absence of 
Usp12 (Figure 1A). This further confirms comprehensive 
analysis by Kee et al. who established that WDR20 binds 
with higher affinity to the complex than to the Usp12 or 
Uaf-1 alone [17]. To establish if this complex is present 
in PC cells, Usp12 was immunoprecipitated from the 
PC LNCaP cell line. Results confirmed the interaction 
between endogenous Usp12, Uaf-1 and WDR20 in PC 
cells (Figure 1B). 
Additionally, we observed that Usp12 protein levels 
were consistently higher when both Uaf-1 and WDR20 
were present. Uaf-1 and WDR20 have previously been 
shown to stimulate Usp12 catalytic activity [17, 18]. 
To determine if these additionally affect Usp12 protein 
stability Uaf-1 and WDR20 were silenced in LNCaP 
cells. Depletion of either complex member reduced 
Usp12 protein levels (Figure 1C). To confirm our findings 
Usp12 was overexpressed either alone or in combination 
with Uaf-1 and WDR20. As predicted Usp12 levels were 
stabilised by the presence of its cofactors (Figure 1D).
To determine if this stabilisation is due to regulation 
at a transcriptional level, mRNA was quantified following 
depletion of each complex member in three different 
PC cell lines. We used LNCaP as a model of androgen 
sensitive disease, LNCaP-AI as a model of androgen 
independent PC and VCaP as a model of AR amplified 
disease with AR variants. Reduction of Uaf-1 diminished 
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the levels of Usp12 transcripts in the LNCaP-AI and VCaP 
cell lines (Figure 1E). Similarly, Usp12 depletion reduced 
both Uaf-1 and WDR20 at an mRNA level. Overall, 
suggesting that this complex may act within a feedback 
loop. This result was further confirmed in patient data. 
We analysed the TCGA database of RNA-seq data and 
observed a significant correlation (p>0.0001 in all three 
cases) between the Usp12, Uaf-1 and WDR20 gene 
expression in PC patient samples (Figure 1F). Additionally, 
ZODIAC analysis [22] of the Usp12 complex copy 
number, gene expression and methylation status in TCGA 
database revealed that Usp12 gene expression levels are 
significantly positively correlated with Uaf-1 and WDR20 
gene expression across all of TCGA sample datasets and 
additionally a positive correlation between Usp12 and 
Uaf-1 methylation was observed (sup fig. 1).
Figure 1: Usp12, Uaf-1 and WDR20 form a complex acting within a positive feedback loop. A. HEK293T cells transfected 
as indicated and incubated for 48 h prior to lysis. Exogenous WDR20 was immunoprecipitated using 1 µg anti-HA antibody and samples 
analysed by immunoblotting. B. Endogenous Usp12 was immunoprecipitated from LNCaP cells and samples probed for the presence of 
Uaf-1 and WDR20 by immunoblotting. IgG antibody was used as a negative control. C. LNCaP cells were subject to 96 h siRNA silencing 
as indicated followed by lysis and immunoblotting. D. pFlag-Usp12, pFlag-Uaf-1 and pHA-Flag-WDR20 were overexpressed in HEK293T 
cells as indicated. Cells were incubated for 48 h prior to lysis and immunoblotted. E. LNCaP, LNCaP-AI or VCaP cells were treated 
with siRNA for 96 h as indicated prior to RNA extraction and quantitative qRT-PCR. All data is normalised to expression of the control 
gene HPRT1 and displayed as expression relative to scrambled (SCR). Error bars represent standard error of the means (SEM) of three 
independent experiments. F. Comparison of Usp12, Uaf-1 and WDR20 gene expression counts from the TCGA RNA sequencing data in a 
prostate cancer dataset (n = 340).
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Figure 2: Uaf-1 and WDR20 form a complex with AR resulting in AR protein stabilisation. A. VCaP cells were cultured 
in full media (FM) or steroid depleted media (SDM) for 96 h prior to lysis. Endogenous AR was immunoprecipitated using 1 µg anti-AR 
antibody or a negative IgG control. Samples were analysed by immunoblotting with both AR isoforms visible (FL AR - full length AR, 
ARv7- AR isoform 7 consisting of exons 1, 2, 3 and cryptic exon 3 [45]). B. COS-7 cells were transfected with pFlag-AR or pHA-Flag-
WDR20 plasmids as indicated. 48 h later cells were harvested and subjected to immunoprecipitation for WDR20 or an IgG control followed 
by immunoblotting. C. LNCaP cells subject to 96 h siRNA knockdown as indicated prior to lysis and immunoblotting. D. LNCaP cells 
were treated with siRNA for 96 h followed by RNA extraction and qRT-PCR analysis normalised to HPRT1 levels. Data is presented as a 
mean of three independent experiments +/- SEM with p values compared to scrambled treated control. E. LNCaP cells were subject to 96 h 
siRNA silencing as indicated followed by lysis and immunoblotting. Where indicated cells were treated with MG132 for 8h prior to lysis. 
F. Comparison of Usp12, Uaf-1 or WDR20 gene expression versus AR from the TCGA prostate cancer dataset (n = 340).
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Uaf-1 and WDR20 interact with and stabilise the 
AR
We have previously established that AR and Usp12 
interact [12]. As both Uaf-1 and WDR20 interact with 
Usp12 we hypothesised that Uaf-1 and WDR20 would 
also be found in a complex with AR. Uaf-1 and WDR20 
were shown to interact with AR and Usp12 endogenously 
in the VCaP cell line (Figure 2A), confirming the presence 
of this complex in PC cells. To assess if WDR20 can 
interact with AR we overexpressed both proteins in 
HEK293T cells. Similarly, we determined that WDR20 is 
found in a complex with AR (Figure 2B). 
We have previously demonstrated that Usp12 is an 
AR coactivator [12]. Given the role of Uaf-1 and WDR20 
in stabilisation and activation of Usp12 we hypothesised 
that depletion of these proteins alone should be sufficient 
to reduce AR protein levels. To investigate this we 
examined AR levels in LNCaP cells following depletion 
of Uaf-1 or WDR20. Importantly, depletion of either 
protein reduced AR levels potentially as a consequence 
of reduction in Usp12 (Figure 2C). This change in AR 
levels is post-translational as depletion of Usp12, Uaf-
1 or WDR20 had no significant effect on AR transcript 
levels (Figure 2D). We have confirmed that this effect on 
AR protein stability was through the ubiquitin proteasome 
system as upon MG132 treatment Usp12, Uaf-1 or 
Figure 3: Uaf-1 and WDR20 are involved in the regulation of AR transcriptional activity. A. Luciferase assay conducted 
in LNCaP-7b7 or LNCaP-AI PSA-Luc cells. Cells were subject to 96 h siRNA treatment in their respective growth media. After 96 h cells 
were imaged at a single time point using IncuCyte to determine cell density. Cells were lysed and luciferase assay conducted. Luciferase 
activity was normalised to cell density to correct for the effect of siRNA treatment on cellular proliferation. Data is displayed as fold change 
compared to SCR. Error bars represent SEM and results are a mean of three independent experiments. B. Luciferase assay conducted in 
HEK293T cells. Cells were starved in steroid-depleted conditions for 24 h prior to transfection with pARE-Luc, pβ-galactosidase and 
additional plasmids as indicated. Cells were incubated for further 24 h before stimulation with 10 nM DHT for the final 24 h. Luciferase 
activity was normalised to β-galactosidase activity to correct for transfection efficiency. Results are displayed as fold change normalised 
to AR overexpression alone. Error bars represent SEM and results are a mean of three independent experiments. C. LNCaP, LNCaP-AI 
or VCaP cells subject to 96 h siRNA treatment as indicated prior to RNA extraction and quantitative qRT-PCR. Data is normalised to 
HPRT1 and displayed as expression relative to SCR. Error bars represent standard error of the mean (SEM) and results are a mean of 
three independent experiments. D. ChIP analysis of AR recruitment at AREIII promoter of PSA. LNCaP cells were subject to 96 h siRNA 
knockdown under steroid-depleted conditions and stimulated with 10 nM DHT 2 h prior to chromatin extraction. ChIP was conducted for 
AR or a negative IgG control. Error bars represent SEM and results are a mean of three independent experiments. 
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WDR20 depletion had no effect on AR protein stability 
(Figure 2E). Interestingly even after the MG132 treatment 
individual complex members were still required for the 
protein stability of the Usp12 complex implying that this 
stabilisation does not occur via deubiquitination (Figure 
2E). 
Our observation was further confirmed in patient 
data when we compared the Usp12, Uaf-1 and WDR20 
gene expression versus that of AR from the TCGA 
database. Counts for all three members of the Usp12 
complex were significantly correlated (p<0.0001) with the 
AR (Figure 2F). The effects of Usp12 complex members 
depletion on AR suggest that targeting Uaf-1 or WDR20 
individually may be as effective as targeting Usp12 
directly while it might provide higher specificity as proved 
in the case of Usp1/Uaf-1 targeting therapeutics. 
Uaf-1 and WDR20 are involved in the regulation 
of AR activity
As Uaf-1 and WDR20 silencing alone was sufficient 
to reduce the AR protein levels we investigated if it would 
affect AR activity. Firstly, luciferase reporter assays were 
conducted following Uaf-1 and WDR20 silencing in the 
LNCaP variant cell line LNCaP-7B7. These cells have a 
stably integrated luciferase gene located downstream of 
the androgen-responsive element of the PSA promoter. We 
have previously used this method to determine that Usp12 
acts as an AR co-activator; Usp12 and AR were therefore 
included as positive controls. Depletion of WDR20, and to 
a lesser extent Uaf-1, reduced AR transcriptional activity 
(Figure 3A). This assay was repeated using a variant of the 
LNCaP-AI cell line generated in the same manner. In this 
cell line silencing of each complex member resulted in a 
dramatic decrease in AR activity (Figure 3A). 
These findings were confirmed by transfecting 
cells with a reporter containing three adjacent androgen-
responsive elements (AREs) upstream from the luciferase 
gene, alongside AR, Usp12, Uaf-1 and WDR20 and 
β-galactosidase for normalisation. Cells were subsequently 
stimulated with dihydrotestosterone (DHT) and receptor 
activity assessed. We have previously demonstrated 
that Usp12/Uaf-1 complex increases AR transcriptional 
activity. Here we demonstrate the importance of 
Figure 4: Uaf-1 and WDR20 regulate PC survival and proliferation. A. LNCaP, LNCaP-AI or VCaP cells were treated with 
siRNA for 96 h as indicated. Cells were cultured in their respective growth media prior to cell counting. Cell count is displayed as fold 
change compared to SCR. Error bars represent SEM and data is a mean of three independent experiments. B. LNCaP cells treated with 
siRNA for 72 h were seeded at equal densities in 6 well plates. Cells were incubated for 14 days prior to staining with crystal violet. 
Colonies were counted and results normalised to SCR. Error bars represent SEM and results are a mean of three independent experiments. 
Representative pictures of the wells are displayed below. C. LNCaP cells subject to 96 h siRNA silencing as indicated. Flow cytometry was 
conducted to detect annexin-V and PI positive cells. Results are normalised to SCR and results are a mean of three independent experiments 
+/- SEM. 
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WDR20 in this process. Interestingly, Usp12/WDR20 
alone significantly increased AR activity but this effect 
was greatest when Usp12, Uaf-1 and WDR20 were 
overexpressed simultaneously (Figure 3B). Cell lines 
used in this study express low levels of endogenous 
Usp12 and Uaf-1, consequently even without the addition 
of Uaf-1 overexpression of WDR20 alone was enough 
to significantly enhance the AR activity. This is a result 
of enhanced activity of the endogenous Usp12 complex 
caused by increased levels of WDR20 which supports our 
data on the positive feedback loop within this complex. 
This further confirms that each complex member alone 
has a limited effect on AR activity but in combination the 
Usp12 complex significantly increases AR transcriptional 
activity implying that targeting any of the binding partners 
should offer the same efficacy as targeting Usp12 alone. 
To further validate our results Usp12, Uaf-1 and 
WDR20 were silenced in three different PC cell lines 
and transcript levels of the AR regulated genes PSA, 
TMPRSS2 and KLK2 determined. Silencing of each 
complex member reduced the transcript levels of all AR 
target genes in LNCaP and LNCaP-AI cells with similar 
effects observed in VCaPs (Figure 3C). Finally, we used 
chromatin immunoprecipitations to show that silencing of 
Uaf-1 or WDR20 reduced AR recruitment to AREIII of 
PSA (Figure 3D).
Overall these results confirm our hypothesis that 
reduction of Uaf-1 or WDR20 alone is sufficient to reduce 
AR activity. The similarity in the reduction of AR activity 
between the cell lines is particularly important as it implies 
that Usp12 complex is a regulator of AR in all stages of PC 
and as such could be a valid therapeutic target in CRPC.
Uaf-1 and WDR20 are involved in PC survival 
and proliferation
To establish if Uaf-1 and WDR20 have a role in 
PC proliferation both complex members were silenced 
alongside Usp12 and AR in different cell line models of 
PC. Proliferation rate was subsequently determined by cell 
counting. Depletion of WDR20 reduced proliferation in 
all tested cell lines, whilst Uaf-1 silencing significantly 
reduced proliferation in the LNCaP-AI cell line (Figure 
4A). Moreover, the ability of LNCaP cells to form colonies 
was significantly reduced following Uaf-1 or WDR20 
depletion (Figure 4B). 
The effect of Uaf-1 and WDR20 depletion on 
cell survival was assessed using Annexin V staining 
to detect apoptotic cells. Staining was quantified using 
flow cytometry and we observed that Uaf-1 and WDR20 
silencing alone significantly increased the levels of 
apoptotic cells (Figure 4C). These results confirm that 
silencing of either Uaf-1 or WDR20 alone is sufficient 
to reduce PC cell proliferation, induce apoptosis and 
reduce colony forming ability. Overall, indicating that 
silencing of the cofactors required for Usp12 activity can 
be as efficient in affecting PC cell growth and survival 
as targeting Usp12 directly. Again the observation that 
silencing of individual complex members can reduce 
proliferation in PC cell lines representing different stages 
of the disease highlights the potential importance of this 
complex in CRPC.
Uaf-1 and WDR20 are biomarkers of PC
We previously demonstrated that Usp12 protein is 
overexpressed in PC compared to benign tissue [12]. We 
therefore predicted that expression of Uaf-1 and WDR20 
would also be increased in PC. To test this we utilised 
a tissue microarray (TMA) containing samples from 
patients with benign prostatic hyperplasia (BPH) and 
PC. Staining for Uaf-1 and WDR20 revealed that both 
proteins were expressed at significantly higher levels in 
the cytoplasm in PC patients compared to benign controls 
(Figure 5A and 5B). A similar trend was observed in the 
nucleus (Figure 5C and 5D). Representative cores from 
each TMA are shown in figure 5E and 5F. The increased 
level of expression of both proteins in PC underlines the 
importance of this complex during disease progression 
and highlights its potential role as a predictive marker and 
therapeutic target. 
DISCUSSION
The AR is a key driver of PC and as such is the 
major therapeutic target in advanced disease. However, 
treatments targeting AR invariably fail and result in the 
development of CRPC. Mechanisms that account for 
this include AR gene mutations, AR gene amplification, 
generation of constitutively active receptor splice variants 
and ligand-independent activation. Importantly, the AR is 
still expressed in CRPC and therefore it remains a viable 
therapeutic target [23]. 
The role of deubiquitination in AR regulation has 
not been extensively studied. Usp10 is known to enhance 
AR transcriptional activity [24, 25] and Usp22 and Usp26 
have been found in complexes with AR [26, 27]. We 
recently identified the deubiquitinating enzyme Usp12 to 
be an AR co-activator [12]. Usp12 is known to function 
as part of a larger complex including the co-factors Uaf-1 
and WDR20 without which Usp12 is catalytically inactive 
[16, 17]. In this report we investigated the role of these co-
factors in regulating Usp12 and AR.
We established that Uaf-1 and WDR20 stabilise 
Usp12 at a protein level and that these cofactors work 
within a positive feedback loop at the mRNA and protein 
levels. We subsequently determined that Uaf-1 and 
WDR20 depletion alone is sufficient to destabilise AR 
and reduce its activity, highlighting the importance of 
this complex in AR regulation. Importantly, the effect of 
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depleting these cofactors on AR activity was comparable 
between the PC cell lines representing both early and 
advanced disease. This suggests that AR is still regulated 
by the Usp12 complex in CRPC highlighting its potential 
as a therapeutic target. As Uaf-1 and WDR20 depletion 
reduces Usp12 levels their silencing has a comparable 
effect on the AR as the Usp12 depletion alone. Similar 
results have been seen in the case of Usp1/Uaf-1 
where knockdown of either protein alone altered the 
ubiquitination status of Usp1 targets PCNA and FANCD2, 
in this example an epistatic relationship between Usp1 
and Uaf-1 was observed [28]. It would be interesting to 
establish if similar principles could be applied to other 
Usp12 targets, for example, we have recently shown 
Usp12 depletion to sensitise PC cells to Akt inhibition 
[13]. It would therefore be worthwhile to investigate if 
individual depletion of Uaf-1 or WDR20 was also capable 
of achieving the same level of sensitisation.
Depletion of Usp12 co-factors decreased colony-
forming ability in LNCaP cells and increased the numbers 
of apoptotic cells. Moreover, both Uaf-1 and WDR20 
proteins were overexpressed in PC tissue. Taken together 
with their effect on AR stability and activity these results 
suggest that the Usp12 complex is worthy of further 
Figure 5: Protein levels of Uaf-1 and WDR20 are increased in PC. A. Prostate TMA stained for Uaf-1. Data represents histoscore 
for cytoplasmic staining of 209 PC samples and 63 BPH samples +/- SEM. B. TMA stained for WDR20. Data represents histoscore for 
cytoplasmic staining of 195 PC samples and 59 BPH samples +/- SEM. C. Prostate TMA stained for Uaf-1. Data represents histoscore 
for nuclear staining of 209 PC samples and 63 BPH samples +/- SEM. D. TMA stained for WDR20. Data represents histoscore for 
nuclear staining of 195 PC samples and 59 BPH samples +/- SEM. E. Representative images of Uaf-1 staining in BPH and PC tissue. F. 
Representative images of WDR20 staining in BPH and PC tissue.
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consideration as a future therapeutic target. In recent 
years, as more DUBs have been linked with cancer, DUB 
inhibitors have become the focus of extensive research. 
Preclinical success has been achieved with the small 
molecule b-AP15 that inhibits Usp14 and UCHL5, two 
DUBs associated with the 19S regulatory particle of 
the proteasome [29]. Several inhibitors of other DUBs 
including Usp7 have also been identified [30-33].
Many of the inhibitors developed against DUBs 
lack specificity, partly owing to the high degree of 
homology between DUB family members. Consequently 
targeting DUB complexes may allow the development 
of more targeted therapeutics. Work is already underway 
to develop inhibitors of the Usp1/Uaf-1 deubiquitinase 
complex. Early reports identified GW7647 and Pimozide 
as weak reversible non-competitive inhibitors, able to 
reverse cisplatin resistance in non-small cell lung cancer 
cells [21]. 
Recently, ML323 and its derivatives were identified 
as more potent and specific Usp1/Uaf-1 inhibitors. 
Authors suggested that ML323 specificity was achieved 
by targeting the DUB complex as opposed to the Usp1 
active site. Again this drug reversed cisplatin resistance 
in non-small cell lung cancer cells [34, 35]. A further 
inhibitor of this complex reduced growth of primary 
human leukemia cells [36]. Overall work by these groups 
has confirmed the druggability of the Usp1/Uaf-1 complex 
and the advantages of complex targeting approach. We 
hypothesise that targeting the Usp12/Uaf-1/WDR20 
complex in a similar manner would allow development 
of therapeutics with greater specificity and sensitivity 
than targeting Usp12 alone. We predict that this would 
be able to reduce AR activity and subsequently reduce 
proliferation of PC cells. 
Interestingly, Usp12, Uaf-1 and WDR20 all contain 
a LXXLL-containing NR box- raising the possibility that 
this complex also interacts with other nuclear hormone 
receptors. It would therefore be worthwhile determining 
if depletion of the Usp12 complex is capable of reducing 
activity of other nuclear hormone receptors such as the 
oestrogen receptor. The cancer atlas within The Human 
Protein Atlas (www.proteinatlas.org) shows that Usp12 
and Uaf-1 are expressed in breast and ovarian cancer 
tissues [37]. 
Finally, we have demonstrated that Uaf-1 and 
WDR20 are overexpressed in PC samples when 
compared to BPH. Taken together with our previous data 
demonstrating Usp12 overexpression in PC [12] this 
suggests that this complex could be a useful marker of 
disease. This is particularly pertinent as there is currently 
an acute lack of prognostic and predictive biomarkers in 
PC. Monitoring of PSA is currently used as part of PC 
diagnosis and as an indicator of recurrence. Although 
useful this method lacks sensitivity and as such has 
several limitations that can lead to over diagnosis and 
overtreatment of PC [38]. The identification of novel 
biomarkers is currently an important area of PC research. 
In conclusion we have shown that Uaf-1 and 
WDR20 depletion reduces AR activity and stability, 
highlighting a further mechanism of AR regulation. 
We have also determined that these two cofactors are 
increased in PC and shown that depletion of these proteins 
alone increases apoptosis of PC cells. Overall this work 
suggests the Usp12 complex is worthy of future research 
to establish if it could be a therapeutic target or biomarker.
MATERIALS AND METHODS
Reagents and antibodies
Antibodies for anti-Usp12, anti-Flag, anti-WDR48 
(Uaf-1) and anti-α-tubulin were purchased from Sigma-
Aldrich. Other antibodies used were: anti-WDR20 (Abcam 
and Santa Cruz, 38K), anti-HA (Santa Cruz Biotechnology, 
Y-11) and anti-AR (Santa Cruz Biotechnology, N-20 and 
C-19). 
Cell culture
Tissue culture reagents were purchased from Sigma-
Aldrich. LNCaP, CWR22Rv1, HEK293T and COS-7 
cells were obtained from the American Type Culture 
Collection (Manassas, VA, USA). LNCaP-AI cells were 
derived in house as previously described [39]. VCaP 
cells were kindly donated by Professor Guido Jenster 
(Erasmus Medical Centre, Rotterdam). LNCaP-7b7 cells 
stably overexpressing pPSA-Luc vector were kindly 
donated by Professor Jan Trapman (Erasmus Medical 
Centre, Rotterdam) and cultured with the addition of 25 
ng/ml Zeocin. LNCaP-AI PSA-Luc cells were generated 
in-house (K. Coffey and S. Walker, unpublished data). 
Cells were maintained in RPMI-1640 media with 2 
mM L-glutamine (Invitrogen) supplemented with 10% 
(v/v) foetal calf serum at 37°C in 5% CO2. LNCaP-AI 
cells were maintained as above in RPMI-1640, 2 mM 
L-glutamine and 10% charcoal treated foetal calf serum, 
denoted steroid depleted media (SDM). 
Plasmids, transfection and siRNA gene silencing
pHA-Flag-WDR20 and pFlag-Uaf-1 were kind 
gifts from Professor Alan D’Andrea (Dana-Farber Cancer 
Institute, Boston). pFlag-Usp12, pPSA-Luc, pARE3-Luc, 
pCMV-β-gal and pFlag-His-AR were previously described 
[12]; [40]. All transfections were conducted using TransIT-
LT1 reagent (MirusBiol) according to manufacturer’s 
instructions. 
Gene silencing was conducted using 25 nM 
siRNA, target sequences and knockdown efficiencies 
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were as previously described [12]. Cells were reverse 
transfected using RNA iMAX (Invitrogen) according to 
manufacturer’s instructions and incubated for 96 h unless 
otherwise indicated. 
Gene expression analysis
RNA was extracted using the EZ RNA isolation kit 
(Biological Industries) and quantified using the Nanodrop 
spectrophotometer (Thermo Scientific). cDNA synthesis 
and qRT-PCR was performed as previously described [41]. 
Chromatin immunoprecipitation (ChIP)
ChIP was conducted as previously described [42] 
essentially following the protocol by Schmidt et al. [43]. 
LNCaP cells were subject to siRNA knockdown in steroid-
depleted conditions for 96 h. 10 nM DHT was applied 
for the final 2 h prior to chromatin extraction. ChIP was 
conducted using anti-AR (Santa Cruz Biotechnology 
C-19) antibody or a negative IgG control. Data is 
presented as percentage input using the following formula: 
% Input=100 x AE (amplification efficiency)*(CT adjusted 
input sample- CT immunoprecipitated sample). CT refers 
to cycle threshold. AREIII primer sequences were as 
follows F: TGGGACAACTTGCAAACCTG and R: 
CCAGAGTAGGTCTGTTTTCAATCCA.
Flow cytometry
Apoptosis was assessed using the Annexin V 
assay (BD Biosciences) on the BD FACScan according 
to manufacturer’s instructions. Assay was conducted 96 
h post silencing and cells were stained with propidium 
iodide (PI) and anti-annexin V. During analysis cells were 
divided into quadrants representing healthy cells, necrotic 
cells and early and late apoptotic cells.
Immunoprecipitation
LNCaP cells were seeded at a density of 
1x106 cells per 90 mm dish, incubated for 96 h and 
immunoprecipitated as previously described [12]. 
Alternatively, HEK293T cells were seeded at a density of 
5x105 per 90 mm dish. After 24 h cells were transfected 
with 1 μg of each of the following plasmids in varying 
combinations: pFlag-AR, pFlag-Usp12, pFlag-Uaf-1 and 
pHA-Flag-WDR20. Cells were incubated for a total of 48 
h prior to immunoprecipitation. 
Luciferase reporter assay
For overexpression studies HEK293T cells 
were seeded to a 24 well plate in SDM and 24 h later 
transfected with 150 ng pARE3-luc, 50 ng pCMV-β-
gal, 10 ng pFlag-His-AR and varying combinations of 
pFlag-Usp12, pFlag-Uaf-1 and pHA-Flag-WDR20 at 10 
ng each. All reactions were balanced with pCMV empty 
vector. Cells were treated with 10 nM DHT 24 h later and 
incubated for a final 24 h prior to lysis in 1x Reporter 
Lysis Buffer (Promega). Lysis solution was mixed with 
Luciferin reagent (Promega) according to manufacturer’s 
instructions and luciferase counts determined using the 
FLUOstar Omega microplate reader (BMG LABTECH). 
Results were normalised to β-galactosidase activity.
For knockdown studies LNCaP-7b7 or LNCaP-AI 
PSA-Luc cells were subject to 96 h siRNA silencing as 
indicated. LNCaP-7b7 cells were grown in SDM for 72 h 
followed by 24 h stimulation with 10 nM DHT. LNCaP-AI 
PSA-Luc cells were cultured in SDM for 96 h. Luciferase 
activity was determined as above and results were 
normalised to cell density determined by live cell imaging 
with IncuCyte ZOOM (Essen Bioscience) immediately 
prior to lysis. 
Proliferation assays
Proliferation was determined by cell counting 
following trypan blue exclusion assay after 96 h of 
continuous siRNA silencing. Percentage cell survival 
compared to scrambled (SCR) control was determined. 
Colony formation assays
LNCaP cells were reverse transfected with siRNA 
and incubated for 72 h. Cells were reseeded over a range 
of cell densities and incubated for 14 days prior to fixing 
with Carnoy’s Fixative and staining with crystal violet. 
Colonies were counted and the fold change in colony 
forming ability compared to SCR control.
Immunohistochemistry
Immunohistochemistry was conducted as previously 
described using 0.01M Citrate buffer at pH 6.0 for antigen 
retrieval [12] with anti-Uaf-1 antibody (Sigma-Aldrich) 
at 1.25μg/μl or anti-WDR20 (Abcam) at 0.04 μg/μl. 
Tissue microarrays (TMAs) were independently scored 
by two scorers using the 0-300 Histoscore [44]. Briefly, 
percentage and intensity of staining for positive cells 
was estimated (0, 1, 2, 3) using the following equation 
Histoscore = (% of cells with low level positivity scored 
as 1 x 1) + (% of cells with medium level positivity scored 
as 2 x 2) + (% of cells with high level positivity scored 
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as 3 x 3). Histoscore was used to independently score 
cytoplasmic and nuclear staining. 
Statistical analysis
All data was first tested for Gaussian distribution. 
In all cases data was found to be parametric and t-test 
was used for further analysis. p values of below 0.05 
were considered statistically significant and marked with 
an asterisk (*). Immunohistopathological analysis was 
performed using non-parametric statistics with previously 
mentioned thresholds applied to p value.
ACKNOWLEDGMENTS
The work was supported by grants from Prostate 
Cancer UK, Newcastle Experimental Cancer Medicine 
Centre (Cancer Research UK, grant: C9380/A15574), 
Newcastle upon Tyne NHS Trustees and Newcastle 
University. Authors would also like to thank Prof. A. 
D’Andrea for donating the Uaf-1 and WDR20 plasmids. 
CONFLICTS OF INTEREST
There is no conflict of interest.
Editorial note
This paper has been accepted based in part on peer-
review conducted by another journal and the authors’ 
response and revisions as well as expedited peer-review 
in Oncotarget.
REFERENCES
1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 
2013. CA Cancer Journal for Clinicians. 2013; 63:11-30.
2. Ryan CJ and Tindall DJ. Androgen Receptor Rediscovered: 
The New Biology and Targeting the Androgen Receptor 
Therapeutically. Journal of Clinical Oncology. 2011; 
29:3651-3658.
3. Feldman BJ and Feldman D. The development of androgen-
independent prostate cancer. Nat Rev Cancer. 2001; 1:34-
45.
4. Palazzolo I, Burnett BG, Young JE, Brenne PL, La Spada 
AR, Fischbeck KH, Howell BW and Pennuto M. Akt blocks 
ligand binding and protects against expanded polyglutamine 
androgen receptor toxicity. Human Molecular Genetics. 
2007; 16:1593-1603.
5. Ogryzko VV, Schiltz RL, Russanova V, Howard BH and 
Nakatani Y. The transcriptional coactivators p300 and CBP 
are histone acetyltransferases. Cell. 1996; 87:953-959.
6. Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal 
DE and Robson CN. Tip60 is a nuclear hormone receptor 
coactivator. The Journal of Biological Chemistry. 1999; 
274:17599-17604.
7. Gaughan L, Logan IR, Cook S, Neal DE and Robson 
CN. Tip60 and histone deacetylase 1 regulate androgen 
receptor activity through changes to the acetylation status 
of the receptor. The Journal of Biological Chemistry. 2002; 
277:25904-25913.
8. Gaughan L, Logan IR, Neal DE and Robson CN. Regulation 
of androgen receptor and histone deacetylase 1 by Mdm2-
mediated ubiquitylation. Nucleic Acids Research. 2005; 
33:13-26.
9. Nishida T and Yasuda H. PIAS1 and PIASxalpha function 
as SUMO-E3 ligases toward androgen receptor and repress 
androgen receptor-dependent transcription. The Journal of 
Biological Chemistry. 2002; 277:41311-41317.
10. Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo 
Z, Chen H, Li W, Kong X, Melamed J, Fang S, Xiao Z, 
Veenstra TD and Qiu Y. Regulation of androgen receptor 
transcriptional activity and specificity by RNF6-induced 
ubiquitination. Cancer Cell. 2009; 15:270-282.
11. McClurg UL and Robson CN. Deubiquitinating enzymes as 
oncotargets. Oncotarget. 2015; 6:9657-9668.
12. Burska UL, Harle VJ, Coffey K, Darby S, Ramsey 
H, O’Neill D, Logan IR, Gaughan L and Robson CN. 
Deubiquitinating enzyme Usp12 is a novel co-activator of 
the Androgen Receptor. Journal of Biological Chemistry. 
2013.
13. McClurg UL, Summerscales EE, Harle VJ, Gaughan L and 
Robson CN. Deubiquitinating enzyme Usp12 regulates 
the interaction between the androgen receptor and the Akt 
pathway. Oncotarget. 2014; 5:7081-7092.
14. Joo HY, Jones A, Yang C, Zhai L, Smith Iv AD, Zhang 
Z, Chandrasekharan MB, Sun ZW, Renfrow MB, Wang Y, 
Chang C and Wang H. Regulation of histone H2A and H2B 
deubiquitination and xenopus development by USP12 and 
USP46. Journal of Biological Chemistry. 2011; 286:7190-
7201.
15. Moretti J, Chastagner P, Liang CC, Cohn MA, Israël A 
and Brou C. The ubiquitin-specific protease 12 (USP12) 
is a negative regulator of notch signaling acting on 
notch receptor trafficking toward degradation. Journal of 
Biological Chemistry. 2012; 287:29429-29441.
16. Cohn MA, Kee Y, Haas W, Gygi SP and D’Andrea AD. 
UAF1 is a subunit of multiple deubiquitinating enzyme 
complexes. Journal of Biological Chemistry. 2009; 
284:5343-5351.
17. Kee Y, Yang K, Cohn MA, Haas W, Gygi SP and D’Andrea 
AD. WDR20 regulates activity of the USP12·UAF1 
deubiquitinating enzyme complex. Journal of Biological 
Chemistry. 2010; 285:11252-11257.
18. Faesen AC, Luna-Vargas MPA, Geurink PP, Clerici M, 
Merkx R, Van Dijk WJ, Hameed DS, El Oualid F, Ovaa 
H and Sixma TK. The differential modulation of USP 
activity by internal regulatory domains, interactors and 
Oncotarget37735www.impactjournals.com/oncotarget
eight ubiquitin chain types. Chemistry and Biology. 2011; 
18:1550-1561.
19. D’Arcy P and Linder S. Molecular pathways: translational 
potential of deubiquitinases as drug targets. Clinical cancer 
research : an official journal of the American Association 
for Clinical Cancer Research. 2014; 20:3908-3914.
20. Liang Q, Dexheimer TS, Zhang P, Rosenthal AS, Villamil 
MA, You C, Zhang Q, Chen J, Ott CA, Sun H, Luci DK, 
Yuan B, Simeonov A, Jadhav A, Xiao H, Wang Y, et al. 
A selective USP1-UAF1 inhibitor links deubiquitination to 
DNA damage responses. Nature Chemical Biology. 2014.
21. Chen J, Dexheimer TS, Ai Y, Liang Q, Villamil MA, 
Inglese J, Maloney DJ, Jadhav A, Simeonov A and Zhuang 
Z. Selective and cell-active inhibitors of the USP1/ UAF1 
deubiquitinase complex reverse cisplatin resistance in non-
small cell lung cancer cells. Chemistry and Biology. 2011; 
18:1390-1400.
22. Zhu Y, Xu Y, Helseth DL, Jr., Gulukota K, Yang S, Pesce 
LL, Mitra R, Muller P, Sengupta S, Guo W, Silverstein 
JC, Foster I, Parsad N, White KP and Ji Y. Zodiac: A 
Comprehensive Depiction of Genetic Interactions in Cancer 
by Integrating TCGA Data. Journal of the National Cancer 
Institute. 2015; 107.
23. Mohler JL, Gregory CW, Ford OH, 3rd, Kim D, Weaver 
CM, Petrusz P, Wilson EM and French FS. The androgen 
axis in recurrent prostate cancer. Clinical cancer research : 
an official journal of the American Association for Clinical 
Cancer Research. 2004; 10:440-448.
24. Faus H, Meyer HA, Huber M, Bahr I and Haendler B. The 
ubiquitin-specific protease USP10 modulates androgen 
receptor function. Molecular and Cellular Endocrinology. 
2005; 245:138-146.
25. Draker R, Sarcinella E and Cheung P. USP10 
deubiquitylates the histone variant H2A.Z and both are 
required for androgen receptor-mediated gene activation. 
Nucleic Acids Research. 2011; 39:3529-3542.
26. Zhao Y, Lang G, Ito S, Bonnet J, Metzger E, Sawatsubashi 
S, Suzuki E, Le Guezennec X, Stunnenberg HG, Krasnov A, 
Georgieva SG, Schule R, Takeyama K, Kato S, Tora L and 
Devys D. A TFTC/STAGA module mediates histone H2A 
and H2B deubiquitination, coactivates nuclear receptors, 
and counteracts heterochromatin silencing. Molecular Cell. 
2008; 29:92-101.
27. Dirac AM and Bernards R. The deubiquitinating enzyme 
USP26 is a regulator of androgen receptor signaling. 
Molecular cancer research : Molecular Cancer Research. 
2010; 8:844-854.
28. Murai J, Yang K, Dejsuphong D, Hirota K, Takeda S and 
D’Andrea AD. The USP1/UAF1 complex promotes double-
strand break repair through homologous recombination. 
Molecular and Cellular Biology. 2011; 31:2462-2469.
29. D’Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten 
K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson 
R and Linder S. Inhibition of proteasome deubiquitinating 
activity as a new cancer therapy. Nat Med. 2011; 17:1636-
1640.
30. Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel 
RH, Ma IT, Rojas Y, Zhao Y, Yu Y, Zhang H, Shohet JM, 
Nuchtern JG, Kim ES and Yang J. USP7 inhibitor P22077 
inhibits neuroblastoma growth via inducing p53-mediated 
apoptosis. Cell Death & Disease. 2013; 4:e867.
31. Yamaguchi M, Miyazaki M, Kodrasov MP, Rotinsulu H, 
Losung F, Mangindaan RE, de Voogd NJ, Yokosawa H, 
Nicholson B and Tsukamoto S. Spongiacidin C, a pyrrole 
alkaloid from the marine sponge Stylissa massa, functions 
as a USP7 inhibitor. Bioorganic & Medicinal Chemistry 
letters. 2013; 23:3884-3886.
32. Weinstock J, Wu J, Cao P, Kingsbury WD, McDermott 
JL, Kodrasov MP, McKelvey DM, Suresh Kumar KG, 
Goldenberg SJ, Mattern MR and Nicholson B. Selective 
Dual Inhibitors of the Cancer-Related Deubiquitylating 
Proteases USP7 and USP47. ACS Medicinal Chemistry 
Letters. 2012; 3:789-792.
33. Reverdy C, Conrath S, Lopez R, Planquette C, Atmanene 
C, Collura V, Harpon J, Battaglia V, Vivat V, Sippl W and 
Colland F. Discovery of specific inhibitors of human USP7/
HAUSP deubiquitinating enzyme. Chemistry & Biology. 
2012; 19:467-477.
34. Liang Q, Dexheimer TS, Zhang P, Rosenthal AS, Villamil 
MA, You C, Zhang Q, Chen J, Ott CA, Sun H, Luci DK, 
Yuan B, Simeonov A, Jadhav A, Xiao H, Wang Y, et al. 
A selective USP1-UAF1 inhibitor links deubiquitination to 
DNA damage responses. Nature Chemical Biology. 2014; 
10:298-304.
35. Dexheimer TS, Rosenthal AS, Luci DK, Liang Q, Villamil 
MA, Chen J, Sun H, Kerns EH, Simeonov A, Jadhav A, 
Zhuang Z and Maloney DJ. Synthesis and structure-activity 
relationship studies of N-benzyl-2-phenylpyrimidin-4-
amine derivatives as potent USP1/UAF1 deubiquitinase 
inhibitors with anticancer activity against nonsmall cell lung 
cancer. Journal of Medicinal Chemistry. 2014; 57:8099-
8110.
36. Mistry H, Hsieh G, Buhrlage SJ, Huang M, Park E, Cuny 
GD, Galinsky I, Stone RM, Gray NS, D’Andrea AD and 
Parmar K. Small-molecule inhibitors of USP1 target 
ID1 degradation in leukemic cells. Molecular Cancer 
Therapeutics. 2013; 12:2651-2662.
37. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, 
Andersen E, Andersson AC, Angelidou P, Asplund A, 
Asplund C, Berglund L, Bergstrom K, Brumer H, Cerjan 
D, Ekstrom M, Elobeid A, et al. A human protein atlas for 
normal and cancer tissues based on antibody proteomics. 
Molecular & Cellular Proteomics : MCP. 2005; 4:1920-
1932.
38. Shtivelman E, Beer TM and Evans CP. Molecular pathways 
and targets in prostate cancer. Oncotarget. 2014; 5:7217-
7259.
39. Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, 
Brady ME, Cook S, Leung HY, Neal DE and Robson CN. 
Oncotarget37736www.impactjournals.com/oncotarget
Expression of Tip60, an androgen receptor coactivator, and 
its role in prostate cancer development. Oncogene. 2002; 
22:2466-2477.
40. Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, 
Neal DE and Robson CN. Tip60 Is a Nuclear Hormone 
Receptor Coactivator. Journal of Biological Chemistry. 
1999; 274:17599-17604.
41. Coffey K, Rogerson L, Ryan-Munden C, Alkharaif D, 
Stockley J, Heer R, Sahadevan K, O’Neill D, Jones D, 
Darby S, Staller P, Mantilla A, Gaughan L and Robson 
CN. The lysine demethylase, KDM4B, is a key molecule in 
androgen receptor signalling and turnover. Nucleic Acids 
Research. 2013; 41:4433-4446.
42. Gaughan L, Stockley J, Coffey K, O’Neill D, Jones DL, 
Wade M, Wright J, Moore M, Tse S, Rogerson L and 
Robson CN. KDM4B is a Master Regulator of the Estrogen 
Receptor Signalling Cascade. Nucleic Acids Research. 
2013; 41:6892-6904.
43. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield 
J and Odom DT. ChIP-seq: Using high-throughput 
sequencing to discover protein-DNA interactions. Methods. 
2009; 48:240-248.
44. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna 
SN, Mukherjee R, Tam L, Munro AF, Dunne B and Bartlett 
JM. Observer variation in immunohistochemical analysis 
of protein expression, time for a change? Histopathology. 
2006; 48:787-794.
45. Dehm SM and Tindall DJ. Alternatively spliced androgen 
receptor variants. Endocrine-Related Cancer. 2011; 
18:R183-196.
